Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Synergys Biotherapeutics Inc
Profile last edited on: 5/21/2021      CAGE: 62PX0      UEI: E365HCJRBKC8

Business Identifier: Antibody therapeutics to treat cancer
Year Founded
2010
First Award
2017
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1945 Arbol Grande
Walnut Creek, CA 94595
   (925) 575-0181
   info@synergysbio.com
   www.synergysbio.com
Location: Single
Congr. District: 11
County: Contra Costa

Public Profile

Synergys Biotherapeutics Inc. has developed a multifunctional antibody biotherapeutics for treatment of cancer. The company is focused on developing vasculogenic mimicry-blocking - a way to block newly defined tumor patterns in highly aggressive tumors. Thus, the company primarily aims to treat cancer and other diseases. The company in-licenses its candidates to other companies for late-stage product development. The company has three products that collectively help treat cancer.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$1,000,000
Phase II Dollars
$0
Total Awarded
$1,000,000

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 1 NIH $400,000
Project Title: Development of Anti-EGFR-huEndo-P125A: a combined Vasculogenic Mimicry-Angiogenesis inhibitory therapeutic for Triple Negative Breast Cancer
2019 1 NIH $300,000
Project Title: Combined Inhibition of Vasculogenic Mimicry and Angiogenesis in Ovarian Cancer Using Antibody Fusion Protein
2017 1 NIH $300,000
Project Title: Targeting angiogenesis and vasculogenic mimicry in Triple Negative Breast Cancer

Key People / Management

  Rathin C Das -- President and CEO

  William S Ammons -- Vice President

  Bruce E Carriwe -- CPA

  Linda Pullan -- Vice President

  Joseph David Rosenblatt

Company News

There are no news available.